Trial · NCT04544293
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24 | From Baseline to Week 24 | Full Analysis Set | % predicted DLCO adjusted for hemoglobin | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Percent (%) Predicted DLCO Adjusted for Hemoglobin Concentration (%DLCOadj) to Week 48 | From Baseline to Week 48 | Unit of Measure: % predicted DLCO adjust | LEAST_SQUARES_MEAN | |
| SECONDARY | Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score to Week 24 | From Baseline to Week 24 | Change from baseline units on a scale | LEAST_SQUARES_MEAN | |
| SECONDARY | Change From Baseline in SGRQ Activity Component Score to Week 24 | From Baseline to Week 24 | units on a scale | LEAST_SQUARES_MEAN | |
| SECONDARY | Change From Baseline in Exercise Capacity (EC), Expressed as Peak Metabolic Equivalents (METs) to Week 24 | From Baseline to Week 24 | Change from baseline in METS | LEAST_SQUARES_MEAN | |
| SECONDARY | Change From Baseline in SGRQ Total Score to Week 48 | From Baseline to Week 48 | Change from baseline units on a scale | LEAST_SQUARES_MEAN | |
| SECONDARY | Change From Baseline in SGRQ Activity From Baseline to Week 48 | From Baseline to Week 48 | Change from baseline score on a scale | LEAST_SQUARES_MEAN | |
| SECONDARY | Change From Baseline in EC, Expressed as Peak METs to Week 48 | From Baseline to Week 48 | Change from baseline in METS | LEAST_SQUARES_MEAN | |
| SECONDARY | Change From Baseline in Alveolar-arterial Oxygen Difference (A-aDO2) to Week 24 (All Subjects) | From Baseline to Week 24 | mmHg | LEAST_SQUARES_MEAN | |
| SECONDARY | Number of Subjects With Serious and Non-serious Adverse Events | From Baseline until End of Double-blind treatment (Week 48) | participants | NUMBER | |
| SECONDARY | Number of Subjects With Positive Treatment-boosted Anti Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Antibody Titers During 24 Weeks' Treatment and During 48 Weeks' Treatment | From Baseline until End of Double-blind treatment Week-48 | One subject in the molgramostim group had missing antiGM-CSF titers. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Changes in Forced Vital Capacity (FVC) %Predicted Normal | From Baseline to Weeks 24 and 48 | % FVC predicted | MEAN | |
| SECONDARY | Changes in Forced Expiratory Volume in One Second (FEV1) % Predicted Normal. | From Baseline to Weeks 24 and 48 | %predicted normal | MEAN | |
| SECONDARY | Change in QT Interval Corrected by Fridericia (QTcF) | From Baseline to Weeks 4 and 24 | Some subjects did not have ECG obtained at some visits. | msec | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04544293/outcomes